Activated PI3K Delta Syndrome care technology platforms are the digital infrastructure underpinning modern management of this rare primary immunodeficiency caused by gain-of-function mutations in the PI3K delta pathway — integrating real-time respiratory function surveillance with bronchiectasis progression tracking dashboards, leniolisib and immunosuppressant therapeutic drug monitoring coordination workflows, CMV and EBV viral load surveillance scheduling, lymphocyte subset immunophenotype tracking platforms, immunoglobulin replacement monitoring systems, lymphoma surveillance coordination, airway clearance adherence tracking dashboards, bronchoscopy and pulmonary function scheduling systems, and patient-reported symptom diaries that enable immunologists and pulmonologists to detect respiratory exacerbations, viral reactivation crises, lymphoma emergence, and treatment-emergent toxicities before they produce irreversible harm. When an APDS care platform is unavailable or degraded, immunologists cannot access the pulmonary function trajectories, CMV and EBV viral load trends, leniolisib trough levels, and bronchiectasis imaging data that guide treatment decisions across the overlapping sinopulmonary immunodeficiency, lymphoproliferation, and oncological complexity of PIK3CD and PIK3R1 gain-of-function disease, therapeutic drug monitoring coordination fails, and the longitudinal clinical monitoring that distinguishes stable APDS from respiratory crisis, EBV-driven lymphoproliferative disease, lymphoma emergence, or bronchiectasis progression collapses. Activated PI3K Delta Syndrome — caused by autosomal dominant gain-of-function mutations in PIK3CD (encoding the PI3K p110δ catalytic subunit, APDS1) or PIK3R1 (encoding the PI3K p85α regulatory subunit, APDS2) — produces constitutively activated phosphatidylinositol 3-kinase delta signaling in lymphocytes; hyperactivated PI3Kδ drives abnormal B-cell development with failure to generate switched memory B cells, increased transitional and immature B cells, impaired terminal plasma cell differentiation, and progressive hypogammaglobulinemia; in T cells, hyperactivated PI3Kδ drives premature T-cell senescence, accumulation of effector memory T cells, and impaired naive T-cell maintenance, producing a combined B- and T-cell defect; the clinical phenotype is dominated by recurrent respiratory tract infections — sinusitis, otitis media, pneumonia — that progress to structural lung disease including bronchiectasis and airway remodeling from repeated inflammatory injury; EBV and CMV infection are particularly poorly controlled, producing EBV-driven lymphoproliferative disease, EBV-associated lymphoma (Hodgkin and non-Hodgkin), and severe CMV end-organ disease in a subset of patients; lymphadenopathy and splenomegaly from lymphocyte accumulation, nodular lymphoid hyperplasia of the gastrointestinal tract, and autoimmune complications including AIHA and ITP are additional features; the PI3Kδ inhibitor leniolisib — approved for APDS in several jurisdictions — corrects PI3Kδ hyperactivation, normalizes B-cell subset distribution, improves immunoglobulin production, and reduces lymphadenopathy; immunoglobulin replacement addresses humoral immunodeficiency-driven infection vulnerability; hematopoietic stem cell transplantation is considered for severe or refractory APDS; mTOR inhibitors reduce lymphoproliferation in selected patients; prophylactic antivirals — valacyclovir, valganciclovir — are important for herpesvirus infection management. The platforms that track pulmonary function trends, CMV and EBV viral loads, leniolisib trough levels, immunoglobulin replacement records, bronchiectasis imaging scores, lymphoma surveillance intervals, lymphocyte subset immunophenotype data, infection episode logs, and airway clearance adherence must remain continuously available — because missed viral load escalation alerts, delayed lymphoma surveillance, leniolisib therapeutic drug monitoring coordination failures, and immunoglobulin trough lapses lead to life-threatening EBV lymphoproliferative crisis, advanced-stage lymphoma, CMV end-organ disease, and the bronchiectasis progression that defines irreversible pulmonary morbidity in inadequately monitored APDS patients.
This guide covers what APDS care technology platforms need to monitor, why continuous availability matters across the spectrum of PI3K delta gain-of-function primary immunodeficiency management, and how to build a monitoring strategy that protects CMV and EBV surveillance, leniolisib therapeutic drug monitoring, pulmonary function tracking, lymphoma surveillance, and the sinopulmonary and oncological management workflows that APDS care requires.
Why APDS Care Tech Platforms Cannot Afford Downtime
APDS management is built on three pillars: correcting PI3Kδ hyperactivation through leniolisib therapy with continuous therapeutic drug monitoring and lymphocyte subset normalization tracking; preventing humoral immunodeficiency-driven bacterial respiratory infections through immunoglobulin replacement and trough level surveillance; and managing the EBV-driven lymphoproliferative disease and lymphoma risk that dysregulated T-cell senescence and impaired viral immune surveillance create. The platforms that support APDS programs must remain continuously available — because an unmonitored patient whose EBV viral load surges during a platform outage and develops EBV lymphoproliferative crisis, or whose leniolisib trough falls below therapeutic range and triggers lymphadenopathy exacerbation while the platform is unavailable, represents a preventable catastrophe that timely digital monitoring could have averted through antiviral escalation or leniolisib dose adjustment.
EBV and CMV viral load surveillance is the primary infectious safety monitoring target. APDS patients with impaired T-cell senescence, reduced naive T-cell maintenance, and deficient CD8+ T-cell cytotoxic responses against EBV and CMV cannot control herpesvirus reactivation — producing EBV-driven lymphoproliferative disease that ranges from infectious mononucleosis-like illness to EBV-positive lymphoma, and CMV retinitis, pneumonitis, and colitis from uncontrolled CMV replication. Digital monitoring platforms that integrate serial EBV and CMV viral load results, generate threshold alerts when viral loads exceed patient-specific intervention levels, track viral load trajectories in response to antiviral therapy, and coordinate urgent oncology and ophthalmology referrals for EBV lymphoproliferative or CMV end-organ complications provide the primary infectious safety infrastructure for APDS; viral load surveillance failures that prevent access to EBV and CMV trajectories create lymphoproliferative and CMV end-organ crisis blind spots that allow viral loads to reach disease-defining levels without antiviral escalation alerts.
Leniolisib therapeutic drug monitoring is mechanism-targeted therapy management. Leniolisib — a selective PI3Kδ inhibitor that corrects the gain-of-function PI3Kδ hyperactivation driving APDS pathophysiology — normalizes B-cell subset distribution including the expansion of switched memory B cells, improves immunoglobulin production, reduces lymphadenopathy, and decreases infection frequency; as a novel small molecule therapy it requires precise therapeutic drug monitoring to maintain efficacious plasma concentrations while avoiding hepatotoxicity, infection risk amplification from excessive PI3Kδ inhibition, and other toxicities. Digital platforms that schedule leniolisib plasma level assessments, track therapeutic window adherence, generate dose adjustment alerts, and monitor for leniolisib toxicity biomarkers provide the pharmacokinetic management infrastructure for APDS mechanism-targeted therapy; trough monitoring failures create therapeutic efficacy gaps where PI3Kδ hyperactivation escapes target inhibition.
Pulmonary function and bronchiectasis surveillance is structural lung disease monitoring. Recurrent sinopulmonary bacterial infections — driven by impaired switched memory B-cell generation and progressive hypogammaglobulinemia — inflict repeated inflammatory injury on airways that produces bronchiectasis, airway remodeling, and progressive obstructive or restrictive ventilatory defect; serial spirometry and CT imaging provide the objective measurements needed to detect bronchiectasis progression, lung function decline, and the airway clearance and antibiotic therapy intensification thresholds that prevent irreversible respiratory impairment. Digital platforms that aggregate serial FEV1, FVC, and flow-volume curve results, track bronchiectasis CT severity scores, generate lung function decline rate alerts, coordinate airway clearance therapy adherence, and schedule prophylactic antibiotic reviews provide the structural lung disease monitoring infrastructure; pulmonary function surveillance failures prevent the early bronchiectasis detection and aggressive antibiotic prophylaxis that slow irreversible airway damage progression.
Lymphoma surveillance is ongoing oncological monitoring. APDS patients carry substantially elevated risk of lymphoma — driven by EBV-driven lymphocyte dysregulation, impaired immune surveillance of EBV-transformed B cells, and lymphoproliferative disease that provides a substrate for malignant transformation; Hodgkin and diffuse large B-cell lymphoma are the most common subtypes, and surveillance with PET-CT or CT imaging at recommended intervals, EBV viral load monitoring, and clinical assessment is required to detect malignancy while curative treatment is feasible. Digital platforms that schedule lymphoma surveillance imaging, track lymph node size and metabolic activity trends, integrate EBV viral load trajectories, generate lymphadenopathy escalation alerts, and coordinate oncology referral workflows provide the malignancy surveillance infrastructure; platform failures that delay imaging or EBV trend alerts allow lymphoma to progress from limited to advanced stage without early intervention.
What to Monitor on an APDS Care Tech Platform
EBV and CMV Viral Load Surveillance Dashboard
The herpesvirus viral load monitoring service — integrating serial EBV PCR and CMV PCR result feeds, viral load threshold alert generation for patient-specific intervention levels, EBV trajectory trend visualization, antiviral therapy response curve tracking, CMV end-organ complication risk scoring, and urgent oncology and ophthalmology referral alert coordination — is the highest-priority infectious safety monitoring target. Check at a 1-minute interval with immediate escalation. EBV and CMV surveillance is the primary mechanism for detecting the viral reactivation that precedes EBV lymphoproliferative crisis, EBV lymphoma, and CMV end-organ disease in a condition where T-cell immunosenescence creates persistent herpesvirus control deficiency; viral load surveillance failures create lymphoproliferative crisis blind spots that allow EBV reactivation to progress unchecked.
Leniolisib Therapeutic Drug Monitoring Platform
Monitor the leniolisib plasma level scheduling coordination service, trough result feed integration, therapeutic window adherence tracking, out-of-range dose adjustment alert generation, and leniolisib toxicity biomarker surveillance (liver function tests, CBC, infection frequency monitoring) at a 1-minute interval. Leniolisib is the mechanism-targeted PI3Kδ inhibitor therapy for APDS; therapeutic drug monitoring platform failures create PI3Kδ inhibition efficacy gaps where lymphadenopathy, B-cell subset abnormalities, and sinopulmonary infection frequency escape therapeutic control from subtherapeutic leniolisib exposure.
Immunoglobulin Replacement and Trough Level Monitoring
Monitor the IVIG or subcutaneous immunoglobulin infusion scheduling coordination platform, immunoglobulin trough level result feed, infusion reaction surveillance system, IgG trough target alert service, and switched memory B-cell reconstitution tracking with leniolisib therapy at a 1-minute interval. Immunoglobulin replacement addresses the hypogammaglobulinemia from impaired switched memory B-cell generation that drives bacterial sinopulmonary infection; trough monitoring failures that allow IgG levels to fall below protective thresholds create infection vulnerability windows that compound APDS respiratory morbidity and bronchiectasis progression.
Pulmonary Function and Bronchiectasis Surveillance Platform
Monitor the spirometry result integration service — including FEV1 and FVC trajectory trend tracking, FEV1/FVC ratio trend visualization, bronchiectasis CT severity score integration, airway clearance therapy adherence tracking, prophylactic antibiotic regimen compliance monitoring, pulmonary exacerbation episode logging, and lung function decline rate alert generation — at a 2-minute interval. Recurrent sinopulmonary infections driving bronchiectasis are the dominant source of irreversible morbidity in APDS; pulmonary function surveillance failures prevent the early airway damage detection and aggressive antibiotic intensification that slow structural lung disease progression.
Lymphoma Surveillance and Oncology Monitoring Platform
Monitor the lymphoma surveillance imaging scheduling service — including PET-CT and CT scan interval management, lymph node size and FDG uptake trend tracking, EBV viral load integration for lymphoproliferative disease risk stratification, lymphadenopathy progression alert generation, and oncology referral workflow coordination — at a 1-minute interval. Lymphoma is the most serious long-term complication of APDS; surveillance platform failures that delay imaging scheduling or EBV trend alerts allow lymphoma to progress from limited stage to unresectable or advanced disease without early detection and curative intervention.
Respiratory Infection Surveillance and Antimicrobial Prophylaxis Dashboard
Monitor the sinopulmonary infection episode logging platform — including recurrent sinusitis, otitis media, and pneumonia tracking, antibiotic course records, prophylactic antibiotic adherence monitoring, bacteriology culture and sensitivity result integration, respiratory pathogen surveillance for emerging resistance patterns, hospitalization episode tracking, and empiric antibiotic escalation decision support — at a 1-minute interval. Recurrent sinopulmonary bacterial infections are the core APDS infectious morbidity driver; infection surveillance failures prevent the infection frequency trend alerting and antibiotic prophylaxis optimization that reduce bronchiectasis progression rate.
Lymphocyte Subset Immunophenotype and B-Cell Reconstitution Tracking
Monitor the peripheral blood B-cell subset quantitation service — including switched memory B-cell percentage tracking, transitional and immature B-cell subset monitoring, T-cell senescence and naive T-cell pool assessment, NK cell count surveillance, leniolisib B-cell normalization response tracking, and immunophenotype trend dashboard — at a 2-minute interval. Abnormal B-cell subset distribution — reduced switched memory B cells, increased transitional B cells — and T-cell senescence markers are the core immunological features of APDS; immunophenotype monitoring tracks the therapeutic normalization response to leniolisib that predicts improved immunoglobulin production and reduced infection frequency.
Lymphadenopathy and Splenomegaly Imaging Surveillance
Monitor the lymph node size dimensional measurement result feed, splenomegaly imaging tracking service, abdominal ultrasound and CT scheduling coordination, and lymphadenopathy progression alert generation at a 2-minute interval. Lymphadenopathy and splenomegaly from lymphocyte accumulation are prominent APDS clinical features that require serial imaging to distinguish stable lymphoproliferation from concerning nodal growth that warrants lymphoma biopsy; imaging surveillance failures prevent the lymph node threshold alerts that guide urgent oncology referral decisions.
Autoimmune Cytopenia CBC Surveillance Dashboard
Monitor the complete blood count aggregation service — including hemoglobin trajectory tracking for AIHA, platelet count trend monitoring for ITP, direct antiglobulin test result integration, and threshold alert generation for cytopenia crises — at a 1-minute interval. Autoimmune hemolytic anemia and immune thrombocytopenia are APDS-associated complications driven by dysregulated B-cell autoreactivity; cytopenia surveillance failures create emergency transfusion and IVIG escalation blind spots that allow hemolytic and thrombocytopenic crises to develop without timely intervention.
Telemedicine and Immunology Coordinator Platform
Monitor the telemedicine session API, immunology and pulmonology nurse coordinator messaging, oncology and infectious disease scheduling coordination, and remote consultation infrastructure at a 2-minute interval. APDS management requires continuous coordination across immunology, pulmonology, oncology, infectious disease, and ophthalmology; platform failures interrupt the multidisciplinary consultation that manages the overlapping herpesvirus infection, lymphoma surveillance, bronchiectasis, leniolisib management, and immunoglobulin replacement domains.
EHR Integration Endpoint
Monitor the EHR synchronization service at a 5-minute interval. APDS patients presenting with fever, new lymphadenopathy, respiratory exacerbation, or visual symptoms require rapid provider access to their EBV and CMV viral load history, current leniolisib regimen, immunoglobulin trough records, pulmonary function trends, and most recent lymphoma surveillance imaging results.
Authentication Service
Monitor authentication at a 1-minute interval. Auth failures lock immunologists, pulmonologists, and APDS care coordinators out of viral load surveillance dashboards, leniolisib trough monitoring platforms, and lymphoma surveillance systems simultaneously — disabling the entire APDS digital management infrastructure.
SSL Certificates Across All Platform Domains
Monitor certificate expiry 30 days in advance across all patient-facing, clinician-facing, and integration domains.
Alerting Strategy for APDS Care Tech Platforms
Immediate clinical escalation (24/7): EBV and CMV viral load surveillance dashboard, leniolisib therapeutic drug monitoring platform, immunoglobulin replacement and trough level monitoring, lymphoma surveillance and oncology monitoring platform, respiratory infection surveillance and antimicrobial prophylaxis dashboard, autoimmune cytopenia CBC surveillance dashboard, authentication service. These affect real-time herpesvirus safety monitoring, mechanism-targeted therapy management, lymphoma detection, and infection prevention continuously.
Immediate clinical operations escalation: Lymphadenopathy and splenomegaly imaging surveillance. Failures here affect lymphoma emergence detection and lymphoproliferative disease monitoring that guide urgent biopsy and oncology referral decisions.
High-priority immediate escalation: Pulmonary function and bronchiectasis surveillance platform, lymphocyte subset immunophenotype and B-cell reconstitution tracking, telemedicine and immunology coordinator platform. Access failures interrupt structural lung disease monitoring, leniolisib therapeutic response tracking, and the multidisciplinary coordination that APDS's complex multi-domain management requires.
Business-hours engineering escalation: EHR synchronization. Investigate within one business hour.
Advance warning: SSL certificate expiry, 30 days in advance, across all patient-facing and integration domains.
EBV viral load surveillance and leniolisib trough monitoring require 24/7 alerting because APDS is a condition of constitutive PI3Kδ activation in which herpesvirus reactivation and lymphoproliferative escalation can develop acutely regardless of time of day — nighttime platform failures that prevent EBV viral load threshold alerts or block leniolisib trough notifications create lymphoproliferative crisis monitoring gaps in a condition where the interval between unrecognized EBV reactivation surge and EBV lymphoproliferative disease, or subtherapeutic leniolisib exposure and lymphadenopathy exacerbation, can be measured in days without the digital monitoring that enables proactive antiviral and PI3Kδ inhibitor escalation.
Status Page as a Clinical Safety Signal
Immunology nurses coordinating after-hours contacts from APDS patients reporting fever, new cervical lymphadenopathy, respiratory exacerbation, or visual changes need immediate platform status awareness before initiating escalation protocols. A published status page allows on-call coordinators to distinguish a platform incident from patient connectivity problems — and to initiate phone-based triage and emergency routing immediately when the digital platform is confirmed unavailable.
For APDS programs coordinating EBV and CMV surveillance, leniolisib trough monitoring, immunoglobulin replacement, and lymphoma surveillance across geographically dispersed patients — many of whom live at a distance from the specialized immunology centers that manage PI3Kδ gain-of-function disease — a status page enables rapid identification of platform failures and activation of manual monitoring protocols. Publish the status page URL in care coordinator workstations, on-call immunology and pulmonology systems, oncology nursing dashboards, and ophthalmology surveillance program coordinators.
The Business Case: Lymphoma Prevention, Pulmonary Preservation, and APDS Program Quality
APDS specialty programs face significant cost exposure from preventable EBV lymphoproliferative crises, advanced-stage lymphoma detection, bronchiectasis-driven respiratory failure, and leniolisib toxicity episodes — with EBV lymphoproliferative disease requiring intensive antiviral and immunosuppressive management, advanced-stage lymphoma requiring multi-agent chemotherapy and transplantation, severe bronchiectasis causing progressive respiratory failure requiring transplant listing, and leniolisib hepatotoxicity requiring drug interruption and management of liver injury. Early EBV viral load detection and antiviral escalation, lymphoma detection at limited stage, and leniolisib-mediated bronchiectasis progression slowing represent the highest-value interventions in APDS management. Platform reliability that supports continuous EBV surveillance and leniolisib trough coordination is upstream of the most catastrophic outcomes in PI3K delta gain-of-function primary immunodeficiency care.
Missed EBV viral load escalation alerts that delay antiviral escalation represent preventable EBV lymphoproliferative crises. Platforms that accurately capture serial EBV and CMV viral load trajectories and integrate them with leniolisib trough levels, immunoglobulin trough records, pulmonary function trends, lymphoma surveillance imaging results, lymphocyte subset immunophenotype data, and infection episode logs enable immunologists to distinguish expected herpesvirus surveillance variation from viral reactivation crisis, expected lymphadenopathy fluctuation from lymphoma emergence, and expected leniolisib concentration variability from therapeutic failure before patients develop EBV-driven lymphoproliferative disease, advanced-stage lymphoma, or irreversible bronchiectasis.
APDS program quality metrics increasingly include EBV lymphoproliferative disease incidence rates, lymphoma detection stage distribution, FEV1 decline rates on leniolisib, IgG trough time-in-range, leniolisib trough time-in-therapeutic-range, and sinopulmonary infection hospitalization rates. Platform reliability is a direct input to outcome quality — programs whose monitoring platforms frequently fail will show higher EBV lymphoproliferative disease rates, later-stage lymphoma detection, faster FEV1 decline, and worse immunoglobulin replacement control in APDS patients who needed continuous herpesvirus surveillance and leniolisib therapeutic drug monitoring coordination.
External monitoring from Vigilmon provides the documented, independent availability record that APDS program directors can present to hospital administration and payer medical directors as evidence that the program's digital infrastructure supports the level of continuous EBV surveillance and leniolisib dosing coordination that PI3Kδ gain-of-function primary immunodeficiency management requires.
Vigilmon Setup for APDS Care Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | EBV and CMV viral load surveillance dashboard | 1 min | PagerDuty (immediate, 24/7) | | Leniolisib therapeutic drug monitoring platform | 1 min | PagerDuty (immediate, 24/7) | | Immunoglobulin replacement and trough level monitoring | 1 min | PagerDuty (immediate, 24/7) | | Lymphoma surveillance and oncology monitoring platform | 1 min | PagerDuty (immediate, 24/7) | | Respiratory infection surveillance and antimicrobial prophylaxis dashboard | 1 min | PagerDuty (immediate, 24/7) | | Autoimmune cytopenia CBC surveillance dashboard | 1 min | PagerDuty (immediate, 24/7) | | Auth service | 1 min | PagerDuty (immediate) | | Lymphadenopathy and splenomegaly imaging surveillance | 2 min | PagerDuty (immediate) | | Pulmonary function and bronchiectasis surveillance platform | 2 min | PagerDuty + Slack (immediate) | | Lymphocyte subset immunophenotype and B-cell reconstitution tracking | 2 min | PagerDuty (immediate) | | Telemedicine and immunology coordinator platform | 2 min | PagerDuty + Slack (immediate) | | EHR synchronization endpoint | 5 min | Slack (business hours) | | SSL: all platform domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add the EBV and CMV viral load surveillance dashboard at a 1-minute interval with 24/7 PagerDuty alerting
- Add leniolisib therapeutic drug monitoring and immunoglobulin trough surveillance at a 1-minute interval with immediate 24/7 escalation
- Add lymphoma surveillance and respiratory infection monitoring at a 1-minute interval with immediate alerting
- Add autoimmune cytopenia CBC monitoring at a 1-minute interval with 24/7 alerting
- Add pulmonary function tracking and lymphadenopathy imaging surveillance at a 2-minute interval with immediate alerting
- Add lymphocyte immunophenotype monitoring and telemedicine platform monitoring with immediate alerting
- Add authentication and EHR synchronization
- Enable SSL monitoring across all patient-facing and integration domains
- Publish the automatic status page URL in care coordinator workstations, on-call immunology and pulmonology systems, oncology nursing dashboards, and ophthalmology surveillance program coordinators
Conclusion
APDS care tech platforms hold the clinical surveillance infrastructure that makes PI3K delta gain-of-function primary immunodeficiency management survivable — EBV and CMV viral load monitoring systems, leniolisib therapeutic drug monitoring coordination dashboards, immunoglobulin replacement trough management platforms, lymphoma surveillance tools, pulmonary function and bronchiectasis tracking systems, autoimmune cytopenia monitoring platforms, and respiratory infection surveillance dashboards that cannot undo the EBV lymphoproliferative crises, advanced-stage lymphomas, irreversible bronchiectasis, and CMV end-organ injuries accumulated during periods of unmonitored herpesvirus reactivation or inadequate leniolisib trough management. Their availability is a prerequisite for lymphoma prevention, pulmonary function preservation, and the specialist access that patients with APDS depend on throughout an illness that requires continuous EBV and CMV surveillance, leniolisib trough management, immunoglobulin replacement monitoring, lymphoma surveillance coordination, pulmonary function tracking, lymphocyte immunophenotype monitoring, and respiratory infection surveillance to maintain therapeutic response, prevent viral crises, and detect the clinical signals — EBV viral load surge, CMV reactivation, leniolisib trough fall, new lymphadenopathy, FEV1 decline, IgG trough drop — that define APDS deterioration before it progresses to the life-threatening EBV lymphoproliferative crises, advanced-stage lymphomas, CMV end-organ disease, and irreversible bronchiectasis that define preventable morbidity in inadequately monitored patients with PIK3CD or PIK3R1 gain-of-function mutations. When EBV surveillance dashboards go offline, leniolisib trough monitoring fails, or lymphoma surveillance platforms are unavailable, the clinical consequences extend to a disease where the difference between adequate and inadequate monitoring is measured in EBV lymphoproliferative hospitalizations, lymphomas detected at unresectable stage, and the APDS lung function losses that occur when PI3Kδ gain-of-function patients are left without the digital monitoring infrastructure that enables proactive antiviral escalation, leniolisib dose adjustment, and the EBV threshold alerting that defines lymphoproliferative risk before it becomes uncontrollable EBV-driven malignancy.
External monitoring from Vigilmon provides the independent, outside-in availability view that APDS program directors and health system IT teams need to catch failures before they affect EBV surveillance or leniolisib trough coordination — with the documented incident record that accreditation bodies and payer audit teams accept as evidence of operational maturity.
Start monitoring your APDS care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and PagerDuty integration. No agent required. No credit card.
Tags: #monitoring #APDS #ActivatedPI3KDeltaSyndrome #PASLI #PIK3CD #PIK3R1 #PI3Kdelta #leniolisib #primaryimmunodeficiency #EBV #CMV #lymphoma #bronchiectasis #hypogammaglobulinemia #immunoglobulinreplacement #immunology #pulmonology #healthtech #uptime #clinicaldocumentation #sre